Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$0.89 USD
-0.02 (-1.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.90 +0.01 (1.51%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STRO 0.89 -0.02(-1.79%)
Will STRO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STRO
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Other News for STRO
Is STRO signaling a buying opportunity? Crossed Above 50 Day Moving Average shows up after surging 5.88%
STRO Fell Below 50 Day Moving Average on September 18
H.C. Wainwright Sticks to Their Hold Rating for Sutro Biopharma (STRO)
Is STRO gathering momentum? NR7 shows up after climbing 0.38%
Technical picture remains unchanged for STRO after it rises 1.29% on September 15